Human breast tumors show great diversity in their morphologies, natural histories and in their responses to therapy. This wide tumor diversity"""""""" poses one of the central challenges to the accurate diagnosis, prevention and treatment of breast tumors. We have used genome-wide gene expression profiling and found that infiltrating ductal and lobular carcinomas of the breast segregated into five distinct and reproducible subtypes [1, 2]. Included within these five subtypes was a new class of tumors that was Estrogen Receptor (ER) and HER2 negative, and which showed characteristics of breast basal/myoepithelial cells. We next demonstrated that this """"""""basal-like"""""""" subtype had on average, the fastest proliferation rates and the shortest overall patient survival times [2]. The development of a prevention strategy for this deadly type of breast tumor is needed because of the unique clinical and biological properties of these tumors. We propose to characterize human basal-like tumors using cellular and genetic assays in order to identify the molecular alterations that are present within this subtype as a first step towards the prevention of this ER-negative subtype of breast tumor. Next, we will determine if breast basal-like tumors progress through a Carcinoma In Situ (CIS) stage, and determine if the most common chemoprevention targets are ever present within these tumors or their precursor lesions. Finally, we will expression profile mouse mammary tumors and compare these results to our human data to identify murine models of basal like tumors, and to identify targets that are present in both hormonally non-responsive animal models and in basal-like tumors of humans.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA101227-02
Application #
6752109
Study Section
Special Emphasis Panel (ZCA1-SRRB-U (J2))
Program Officer
Lubet, Ronald A
Project Start
2003-05-28
Project End
2008-04-30
Budget Start
2004-05-01
Budget End
2005-04-30
Support Year
2
Fiscal Year
2004
Total Cost
$396,382
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Genetics
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ellis, Matthew J; Perou, Charles M (2013) The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 3:27-34
Nguyen, David H; Fredlund, Erik; Zhao, Wei et al. (2013) Murine microenvironment metaprofiles associate with human cancer etiology and intrinsic subtypes. Clin Cancer Res 19:1353-62
Prat, Aleix; Perou, Charles M (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5-23
Chandriani, Sanjay; Frengen, Eirik; Cowling, Victoria H et al. (2009) A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One 4:e6693
Hennessy, Bryan T; Gonzalez-Angulo, Ana-Maria; Stemke-Hale, Katherine et al. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116-24
Thorner, A R; Hoadley, K A; Parker, J S et al. (2009) In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene 28:742-51
Hu, Zhiyuan; Fan, Cheng; Livasy, Chad et al. (2009) A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 7:9
Millikan, Robert C; Newman, Beth; Tse, Chiu-Kit et al. (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123-39
Shabalin, Andrey A; Tjelmeland, Hakon; Fan, Cheng et al. (2008) Merging two gene-expression studies via cross-platform normalization. Bioinformatics 24:1154-60
Wright, Mollie H; Robles, Ana I; Herschkowitz, Jason I et al. (2008) Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol Cancer 7:29

Showing the most recent 10 out of 26 publications